Overview
PUVA (Psoralen plus UVA) therapy is associated with an increased risk of skin malignancies, particularly squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), due to prolonged exposure to ultraviolet radiation 1.Diagnosis
Clinical examination revealing suspicious skin lesions
Histopathological confirmation via biopsy for definitive diagnosis 1Management
Regular dermatological surveillance for early detection of skin malignancies 1
Discontinuation of PUVA therapy upon detection of skin malignancies 1
Surgical excision or other local treatments as indicated for diagnosed malignancies 1Special Populations
No specific guidelines provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1Key Recommendations
Implement rigorous dermatological surveillance in patients undergoing PUVA therapy to monitor for skin malignancies (Evidence: Moderate) 1
Discontinue PUVA therapy if any skin malignancy is diagnosed to mitigate further risk (Evidence: Moderate) 1
Tailor follow-up schedules based on individual risk factors, though specific dosing or pediatric/elderly guidelines are not detailed (Evidence: Expert opinion) 1References
1 Nakamura M, Chida K, Inaba Y, Kobayashi R, Zuguchi M. Red-emission phosphor's brightness deterioration by x-ray and brightness recovery phenomenon by heating. Journal of radiological protection : official journal of the Society for Radiological Protection 2017. link